Usefulness of recommbinant thrombomodulin (rTM) in the prevention for hematopoietic stem cell transplantation related complication: multicenter joint research project

Usefulness of recommbinant thrombomodulin (rTM) in the prevention for hematopoietic stem cell transplantation related complication: multicenter joint research project - NEWS-RT (New SIGHT Research in Transplantation)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030426

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic stem cell transplantation

Interventions

from conditioning to day 21 after HST Nothing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. BMT or PBSCT 2. recovery patients 3. Performance status (PS) 0-2 4. HLA compatible (5/6) 5. good function of internal organs (heart, lung, liver and kidney) and SpO2 >95% 6. MAST conditioning 7. creatinine < 1.5 mg/dL 8. AST and ALT < 100 U/L 9. Age 20- 65 years 10. informed concent

Exclusion criteria

Exclusion criteria: 1. severe complications 2. contraindication of rTM 3. sensitivity for rTM 4. eGFR < 30mL/min/1.73m2 5. pregnancy, rectation period 6. inappropriate patients

Design outcomes

Primary

Measure	Time frame
Comparison between two groups for hematopoietic stem cell transplantation-related complication in periods from day 0 to day 28	—

Secondary

Measure	Time frame
Comparison between two groups for some biomarkers in periods from day 0 to day 28	—

Countries

Japan

Contacts

Public ContactShosaku Nomura

Kansai Medical University First Department of Internal Medicine

nomurash@hirakata.kmu.ac.jp072-804-2754

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026